News Updates
More Articles
- MorphoSys unveils tie-ups with Pfizer, Incyte and HIBio
- Boehringer to acquire Trutino via signed option
- Sanofi, GSK tout data from trials for COVID-19 booster
- EU OKs DDM platform from Sophia Genetics
- Collaborative effort to boost global access to cefiderocol
Ariceum raises funds for satoreotide development
Ariceum Therapeutics raised $26.7 million from a Series A funding round to develop its main radiopharmaceutical drug. Satoreotide is being developed to use in the diagnosis and treatment of tumors expressing the somatostatin type 2 receptor, and Ariceum aims to have three clinical trials underway next year. Endpoints News (free registration) (6/8)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!